Dermatitis News and Research RSS Feed - Dermatitis News and Research

Dermatitis is an infection of the skin. The skin may become itchy and progress to a bumpy red rash that may become tender. There may also be pus-filled blisters that are usually found surrounding hair follicles.
Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Anacor Pharmaceuticals enrolls first patient in AN2728 Phase 3 trial for treatment of atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been enrolled in the Phase 3 trial of AN2728, a novel boron-based phosphodiesterase-4 (PDE-4) inhibitor, for the topical treatment of mild-to-moderate atopic dermatitis. Atopic dermatitis is a chronic rash characterized by inflammation and itch and affects approximately 10% - 20% of infants and young children. [More]
Derma Sciences' net sales increase 3% to $20.7 million in fourth quarter 2013

Derma Sciences' net sales increase 3% to $20.7 million in fourth quarter 2013

Derma Sciences, Inc., a tissue regeneration and burn care company focused on advanced wound care, today reported financial and operating results for the three months and year ended December 31, 2013. [More]
Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg. [More]

Pre-moistened wipes linked to dramatic rise in allergic reactions, says dermatologist

More and more people are developing an itchy, painful rash in an effort to stay clean. A dermatologist at The Ohio State University Wexner Medical Center says a preservative in many types of pre-moistened wipes is linked to a dramatic rise in allergic reactions. [More]
Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare. [More]
Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st. [More]

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO). [More]
FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults. [More]

BMG Pharma signs agreement with Samyang Biopharmaceutical to market GelX in South Korea

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with Samyang Biopharmaceutical Corporation granting them the rights to promote, sell and market its novel mucositis management product GelX in the territory of South Korea. [More]
Researchers examine quality of needles used in acupuncture

Researchers examine quality of needles used in acupuncture

The quality of needles used in acupuncture worldwide is high but needs to be universally improved to increase safety and avoid potential problems such as pain and allergic reactions, RMIT University researchers have found. [More]
Zoetis reports revenue of $1.25 billion for Q4 2013

Zoetis reports revenue of $1.25 billion for Q4 2013

Zoetis Inc. today reported its financial results for the fourth quarter and full year 2013. The company reported revenue of $1.25 billion for the fourth quarter of 2013, an increase of 7% from the fourth quarter of 2012. Revenue reflected an operational increase of 9%, with foreign currency having a negative impact of 2 percentage points. [More]
Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt today announced the commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees. [More]
Mother's illness, allergen exposure during pregency may predict child's risk of asthma and allergy

Mother's illness, allergen exposure during pregency may predict child's risk of asthma and allergy

Women that are pregnant may want to take extra precaution around those that are sniffling and sneezing this winter. According to a new study published today, the more common colds and viral infections a woman has during pregnancy, the higher the risk her baby will have asthma. [More]

Research report on global atopic dermatitis market

Reportlinker.com announces that a new market research report is available in its catalogue: PharmaPoint: Atopic Dermatitis - Current and Future Players [More]
FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

FDA meeting streamlines pathway to initial U.S. approval of Provectus's PV-10 oncology drug

Provectus Biopharmaceuticals, Inc. (PVCT), a development-stage oncology and dermatology biopharmaceutical company, today announced that it has received the official minutes from the Type C meeting held with the FDA's Division of Oncology Products 2 on December 16, 2013. [More]
Loyola professor receives prestigious Presidential Early Career Award for Scientists and Engineers

Loyola professor receives prestigious Presidential Early Career Award for Scientists and Engineers

Katherine Radek, PhD, of Loyola University Chicago Stritch School of Medicine, has received a prestigious Presidential Early Career Award for Scientists and Engineers. [More]

FDA approves New Drug Application for PENNSA 2%

Mallinckrodt today announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s). [More]

RoundTable Healthcare Partners sells Aqua Pharmaceuticals Holdings for $402.6M to Almirall

RoundTable Healthcare Partners, an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has completed the sale of Aqua Pharmaceuticals Holdings, Inc. to Almirall S.A. for up to $402.6 million in cash [More]

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults. [More]

Discovery opens new therapeutic avenue for chronic skin condition affecting millions

Researchers from the La Jolla Institute for Allergy and Immunology have revealed a critical player in the cellular interactions leading to eczema - a chronic inflammatory skin condition affecting more than 14 million U.S. children and adults. [More]